<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03736512</url>
  </required_header>
  <id_info>
    <org_study_id>U0597</org_study_id>
    <nct_id>NCT03736512</nct_id>
  </id_info>
  <brief_title>China Greenlight Registry Study (Post-market)</brief_title>
  <official_title>Prospective Registry of Outcomes With the GreenLight™ Laser System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The duration of the study is expected to take approximately 3 years, which includes a&#xD;
      recruitment period of approximately 12-months and 2 years (24-months) to complete procedure&#xD;
      and follow-up visits.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study follow-up duration from the primary study procedure is 5 years.&#xD;
&#xD;
        -  Baseline&#xD;
&#xD;
        -  Study Procedure&#xD;
&#xD;
        -  4-week&#xD;
&#xD;
        -  6-month&#xD;
&#xD;
        -  12-month&#xD;
&#xD;
        -  24-month (End of Study) The study will be considered complete after all subjects have&#xD;
           completed the 24-month follow-up visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 27, 2019</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Actual">March 30, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>The GreenLight XPS system provides durable relief of BPH symptoms in subjects.</measure>
    <time_frame>6-month follow up</time_frame>
    <description>Changes of IPSS Scores in subjects treated with the GreenLight XPS Laser System at 6 months</description>
  </primary_outcome>
  <enrollment type="Actual">30</enrollment>
  <condition>Benign Prostatic Hyperplasia (BPH)</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GreenLight XPS™ 532 nm Laser System with MoXy™ laser fiber</intervention_name>
    <description>observational registry</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Men diagnosed with benign prostatic hyperplasia (BPH) for whom GreenLight Laser therapy is&#xD;
        recommended by their physician and eligible for inclusion.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has provided informed consent and agrees to attend all study visits&#xD;
&#xD;
          -  Subject has a diagnosis of lower urinary tract symptoms due to benign prostatic&#xD;
             enlargement causing bladder outlet obstruction&#xD;
&#xD;
          -  Subject is able to complete self-administered questionnaires&#xD;
&#xD;
          -  Clinical investigator has documented in the subject's medical record that in his/her&#xD;
             judgment the subject is a surgical candidate for the PVP procedure&#xD;
&#xD;
          -  Subject is ≥ 40 years of age&#xD;
&#xD;
          -  Subject has an IPSS score greater than or equal to 12 measured at the baseline visit&#xD;
&#xD;
          -  Subject has medical record documentation of a maximum urinary flow rate (Qmax) less&#xD;
             than or equal to 15ml/s and sample is greater than or equal to 150ml (If uroflow&#xD;
             testing documentation is available within 90 days prior to the informed consent date,&#xD;
             and the sample is greater than or equal to 150ml, and the Qmax is less than or equal&#xD;
             to 15ml/s it may be used for the inclusion/exclusion criteria)&#xD;
&#xD;
          -  Subject has medical record documentation of a prostate volume of greater than or equal&#xD;
             to 30 grams by transrectal ultrasound (TRUS))&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has a life expectancy of less than 2 years&#xD;
&#xD;
          -  Subject is classified as American Society of Anesthesiologists (ASA) V&#xD;
&#xD;
          -  Subject is currently enrolled in, or plans to enroll in, any concurrent drug or device&#xD;
             study unless preapproved by the sponsor&#xD;
&#xD;
          -  Subject has an active infection that would preclude operation within 14 days of the&#xD;
             study procedure (e.g., urinary tract infection or prostatitis)&#xD;
&#xD;
          -  Subject has a diagnosis of, or has received treatment for, chronic prostatitis or&#xD;
             chronic pelvic pain syndrome (e.g., non-bacterial chronic prostatitis)&#xD;
&#xD;
          -  Subject has a neurogenic bladder or other neurological disorder that would impact&#xD;
             bladder function (e.g., multiple sclerosis, Parkinson's disease, spinal cord injuries)&#xD;
&#xD;
          -  Subject has a diagnosis of polyneuropathy (e.g., diabetic)&#xD;
&#xD;
          -  Subject has diagnosis of stress urinary incontinence that requires treatment or daily&#xD;
             pad/device use&#xD;
&#xD;
          -  Subject has a diagnosis of prostate cancer or suspected prostate cancer based on PSA&#xD;
             results and meeting the following:&#xD;
&#xD;
        PSA level of 4 - 10 with an abnormal DRE (if biopsy collected must be positive); PSA level&#xD;
        greater than 10 with a positive biopsy&#xD;
&#xD;
          -  Subject has a history of CIS, TaGIII or any T1 stage bladder cancer&#xD;
&#xD;
          -  Subject has damage to external urinary sphincter&#xD;
&#xD;
          -  Subject has had an acute myocardial infarction, open heart surgery or cardiac arrest&#xD;
             less than 180 days prior to the date of informed consent&#xD;
&#xD;
          -  Subject is immunocompromised (e.g., organ transplant, leukemia)&#xD;
&#xD;
          -  Subject currently or has a history of upper urinary tract stones&#xD;
&#xD;
          -  Subject currently diagnosed with OAB and treated with medication If the subject does&#xD;
             not carry a diagnosis but is suspected to have OAB, the investigator must use his/her&#xD;
             discretion&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Men diagnosed with benign prostatic hyperplasia (BPH) for whom GreenLight Laser therapy is recommended by their physician and eligible for inclusion.</gender_description>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhiyu Zeng, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Boston Scientific Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sun Yat-sen Memorial Hosptital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 4, 2017</study_first_submitted>
  <study_first_submitted_qc>November 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2018</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

